Photodynamic diagnosis of ovarian cancer by 5-aminolevulinic acid and establishment of novel treatment

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K10713
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Obstetrics and gynecology
• Research Institution: Aichi Cancer Center Research Institute
• Principal Investigator: Mika Mizuno 愛知県がんセンター(研究所), 腫瘍免疫学部, 研究員 (50588837)
• Co-Investigator(Kenkyū-buntansha): 柴田 清住 藤田保健衛生大学, 医学部, 教授 (90335026)
• Co-Investigator(Renkei-kenkyūsha): KAJIYAMA Hiroaki 名古屋大学, 医学系研究科, 准教授 (00345886)
• Research Collaborator: TESHIGAWARA Toshiya ; ISHII Takuya ; ISHIZUKA Masahiro
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 5-aminolevulinic acid / Photodynamic therapy / 卵巣がん / 難治性癌

Outline of Final Research Achievements

Photodynamic therapy (PDT) is known as a minimally invasive treatment for cancer. 5-Aminolevulinic acid (ALA) is a precursor of the photosensitizing agent protoporphyrin IX (PpIX). We evaluated the efficacy of ALA-PDT and investigated relevant factors of enhancement of effect on various　ovarian cancer cells in vitro and in vivo.
We confirmed the effect of ALA-PDT using various ovarian cancer cell lines. Especially,we found that three cell lines of clear cell carcinoma, which is chemoresistance tumor,were also highly sensitive to ALA-PDT.The cell lines sensitive to ALA-PDT expressed PEPT1 (an ALA uptake transporter) adn the cell line resistant to ALA-PDT expressed ABCG2 (a PpIX export transporter). In the resistant cell line, a combination treatment with both ALA and an ABCG2 inhibitor resulted in the promotion of cytotoxic sensitivity in vitro.

Free Research Field

婦人科悪性腫瘍